Synaffix BV news

• Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload)
• Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline
• Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties

• Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology 
• CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-i

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022.

This marks the second time that Synaffix’ groundbreaking ADC platform technology has been acknowledged as industry-leading by winning 1^st 

• Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs
• Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target
• Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology
• Triggers $5 million immediate payment to Synaffi

• Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs
• SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan
• Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020)

Synaffix B.V., a biotechnology company focused on commercializing its clinical-